Emblem Corp. and Canntab Therapeutics Limited announced the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids, which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab's partnership to develop long-acting cannabis formulations. Canntab has brought development and processing equipment to Emblem's Paris, Ontario location and will begin making the first pivotal batch of the Product this week using its patented technology and proprietary processes. This initial batch will undergo rigorous testing both internally by Emblem and Canntab and externally by third-party laboratories. Upon achievement of the Product`s target design criteria, Emblem and Canntab intend to submit a full dossier to Health Canada for review and approval.